Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-03-28 Declaration of Voting R…
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement titled '정기주주총회결과' (Annual General Meeting Results) for Il-Yang Pharmaceutical. It details the outcomes of the meeting, including the approval of financial statements, dividend declarations, and the election of board members. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the official results of shareholder votes at the AGM.
2025-03-28 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previously submitted Audit Report. It details specific financial adjustments (assets, liabilities, equity, and profit/loss) due to changes in the consolidation scope of subsidiaries. Since it is a formal regulatory filing detailing financial corrections and audit-related data rather than the full annual report itself, it falls under the category of regulatory filings. FY 2022
2025-03-27 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Il-Yang Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It specifically details a 'Correction Report' (정정신고) regarding previously submitted audit data due to changes in the consolidation of a subsidiary. It provides updated financial tables (assets, liabilities, equity, profit/loss) for both consolidated and separate financial statements. Since this is a formal regulatory filing containing audited financial data and corrections to previous filings, it falls under the 'Audit Report / Information' category. FY 2023
2025-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is an official 'Audit Report Submission' (감사보고서 제출) filed by Il-Yang Pharmaceutical. It contains the auditor's opinion (적정 - Unqualified), financial statements (consolidated and separate), and details regarding the accounting firm. While it provides financial data, it is a regulatory filing specifically announcing the receipt and submission of the audit report as required by Korean financial regulations, rather than the full Annual Report (10-K) itself. Therefore, it is classified as an Audit Report/Information document. FY 2024
2025-03-27 Korean
[기재정정]사업보고서 (2022.12)
Regulatory Filings Classification · 95% confidence The document is a 'Correction Report' (정정신고) for an 'Annual Business Report' (사업보고서) filed by Il-Yang Pharmaceutical Co., Ltd. It details specific corrections made to previously filed financial statements, including changes to the consolidation status of subsidiaries and subsequent adjustments to financial data. As it is a formal regulatory filing correcting a previously submitted annual report, it falls under the category of regulatory filings. FY 2022
2025-03-27 Korean
[기재정정]사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Il-Yang Pharmaceutical Co., Ltd. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, etc.), and notes to the financial statements. It explicitly mentions a correction (정정) of previously filed financial statements due to adjustments in consolidated subsidiaries. As it is a comprehensive audit report containing financial statements and auditor's opinion, it falls under the 'Audit Report' category. FY 2023
2025-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.